Literature DB >> 11569526

High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.

S A Roberts1.   

Abstract

1. High-throughput screening approaches have been adopted throughout the pharmaceutical industry to aid in the rapid discovery of new chemical entities. Because it is now well recognized that the selection of a robust candidate requires a balance of potency, safety and pharmacokinetics, the role of drug metabolism departments has widened from their traditional one of supporting drug development to include the screening of compounds during the discovery process. To put drug metabolism and pharmacokinetic (DMPK) studies in context, the evolving role of DMPK screening in the drug discovery strategy of pharmaceutical companies will be discussed and a generalized approach will be presented. 2. With the increasing numbers of compounds requiring screening, DMPK optimization methods have had to be adapted for high throughput. There have been many developments in this field over the past decade and this review will focus on the high-throughput DMPK screening methodologies used today and in the recent past. 3. In vitro and in silico (computer-based) methods have proven most amenable to high-throughput approaches and these will firm the bulk of the review, but some advances with in vivo methods will also be discussed. As there has been a vast increase in published material on the topic of high-throughput DMPK methodologies in the past 10 years, it would be impossible to cover every method in detail, so this review will concentrate on the key areas and refer the reader to other, more detailed reviews wherever possible. 4. Most high-throughput methods would not be possible without the enabling technologies of computing, automation, new sample preparation technologies, and highly sensitive and selective detection systems, and these will also be reviewed. 5. The advantages and disadvantages of the screening methods will be presented, in particular the issue of handling the false-positives and -negatives that arise. 6. In concluding the review, future developments in this field will be discussed along with key issues that will need to be addressed.

Mesh:

Substances:

Year:  2001        PMID: 11569526     DOI: 10.1080/00498250110060978

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Toxicity testing in the 21st century: a vision and a strategy.

Authors:  Daniel Krewski; Daniel Acosta; Melvin Andersen; Henry Anderson; John C Bailar; Kim Boekelheide; Robert Brent; Gail Charnley; Vivian G Cheung; Sidney Green; Karl T Kelsey; Nancy I Kerkvliet; Abby A Li; Lawrence McCray; Otto Meyer; Reid D Patterson; William Pennie; Robert A Scala; Gina M Solomon; Martin Stephens; James Yager; Lauren Zeise
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2010-02       Impact factor: 6.393

2.  Rapid in vivo oral screening in rats: reliability, acceptance criteria, and filtering efficiency.

Authors:  Hong Mei; Walter Korfmacher; Richard Morrison
Journal:  AAPS J       Date:  2006-07-28       Impact factor: 4.009

3.  Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.

Authors:  Rama K Mishra; Kristine K Deibler; Matthew R Clutter; Purav P Vagadia; Matthew O'Connor; Gary E Schiltz; Raymond Bergan; Karl A Scheidt
Journal:  J Chem Inf Model       Date:  2019-10-14       Impact factor: 4.956

Review 4.  Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.

Authors:  Kwame N Atuah; Dyfrig Hughes; Munir Pirmohamed
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  High-throughput 1,536-well fluorescence polarization assays for α(1)-acid glycoprotein and human serum albumin binding.

Authors:  Adam Yasgar; Silviya D Furdas; David J Maloney; Ajit Jadhav; Manfred Jung; Anton Simeonov
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

6.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.

Authors:  K-C Cheng; Walter A Korfmacher; Ronald E White; F George Njoroge
Journal:  Perspect Medicin Chem       Date:  2007-06-26

7.  An ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans.

Authors:  Chi K Leung; Ying Wang; Siobhan Malany; Andrew Deonarine; Kevin Nguyen; Stefan Vasile; Keith P Choe
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.